Third-generation Cephalosporin resistance in Sub-Saharan Africa: a systematic review and meta-analysis
Open Access
- 18 November 2025
- journal article
- review article
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Abstract
Background Antimicrobial resistance is a critical global health threat, with Sub-Saharan Africa disproportionately affected. Third-generation cephalosporins are widely used for severe infections due to their safety, broad spectrum, and effectiveness. However, resistance to third-generation cephalosporins undermines treatment and exacerbates poor outcomes in regions with limited alternative therapies. This systematic review and meta-analysis evaluated the prevalence, temporal trends, and geographical variations of resistant pathogens in Sub-Saharan Africa. Methods We searched three databases from the inception until 16th August 2024 for observational studies reporting third-generation cephalosporin resistant infections in Sub-Saharan Africa. Eligible studies reported prevalence data for confirmed infections in SSA. Pooled prevalence estimates with 95% confidence intervals (CIs) were calculated using random-effects meta-analysis, with subgroup analyses by pathogen, region, clinical setting, and publication year. Results Here we show a total of 200 studies involving 355,136 patients. The pooled prevalence of third-generation cephalosporin resistant pathogens is 45.3% (95% CI: 36.7–54.4%). Resistance rates are highest for Klebsiella pneumoniae (57.7%) and Enterobacter spp. (54.2%). Temporal trends show an increase in resistance, with prevalence rising from 22.8% before 2009 to 42.0% in 2020–2024. Geographical disparities are evident, with higher prevalence in East (59.7%) and West Africa (49.8%) compared to Central Africa (27.0%). High-risk settings include neonatal intensive care units, surgical wards, and rural or mixed-care facilities. Conclusions Third-generation cephalosporin resistant pathogens represent an escalating global health crisis in SSA, exacerbated by regional disparities and rising resistance rates over time. Immediate interventions are needed, including enhanced surveillance and antimicrobial stewardship programs.Keywords
Funding Information
- This research was partially supported by EU funding within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
This publication has 36 references indexed in Scilit:
- Antibiotic Resistance in Developing Countries: Emerging Threats and Policy ResponsesPublic Health Challenges, 2025
- Carriage of third-generation cephalosporin-resistant and carbapenem-resistant Enterobacterales among children in sub-Saharan Africa: a systematic review and meta-analysiseClinicalMedicine, 2024
- Quality of Antibiotic Use in Developing Countries: Status and Future Recommendations2023
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysisThe Lancet, 2022
- Assessing the quality of studies in meta‐research: Review/guidelines on the most important quality assessment toolsPharmaceutical Statistics, 2020
- Cochrane Handbook for Systematic Reviews of Interventions2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreementJournal of Clinical Epidemiology, 2012
- Hospital-acquired neonatal infections in developing countriesThe Lancet, 2005
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986